Marinus Pharmaceuticals (MRNS)
(Real Time Quote from BATS)
$1.47 USD
+0.04 (2.80%)
Updated Jul 22, 2024 01:04 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Marinus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 31 | 25 | 15 | 2 | 0 |
Cost Of Goods | 2 | 0 | 1 | 0 | 0 |
Gross Profit | 29 | 25 | 14 | 2 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 161 | 138 | 111 | 70 | 54 |
Income After Depreciation & Amortization | -131 | -113 | -97 | -68 | -54 |
Non-Operating Income | 5 | 107 | 1 | 0 | 0 |
Interest Expense | 17 | 11 | 3 | 0 | 0 |
Pretax Income | -143 | -16 | -99 | -67 | -54 |
Income Taxes | -2 | 3 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -141 | -20 | -99 | -67 | -54 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -141 | -20 | -99 | -67 | -54 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -131 | -112 | -96 | -68 | -54 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -131 | -113 | -97 | -68 | -54 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 53.75 | 39.07 | 36.66 | 27.27 | 13.63 |
Diluted EPS Before Non-Recurring Items | -2.63 | -2.75 | -2.69 | -2.80 | -3.96 |
Diluted Net EPS (GAAP) | -2.63 | -0.51 | -2.69 | -2.80 | -3.96 |
Fiscal Year end for Marinus Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 7.68 | 7.19 | 7.34 | 6.08 |
Cost Of Goods | NA | 0.76 | 0.89 | 0.46 | 0.39 |
Gross Profit | NA | 6.92 | 6.30 | 6.88 | 5.70 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 42.75 | 41.74 | 38.53 | 37.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -35.83 | -35.44 | -31.65 | -31.43 |
Non-Operating Income | NA | 1.50 | -2.03 | 2.92 | 2.18 |
Interest Expense | NA | 4.35 | 4.30 | 4.24 | 4.21 |
Pretax Income | NA | -38.67 | -41.77 | -32.97 | -33.47 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | -1.54 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -38.67 | -41.77 | -32.97 | -31.93 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -38.67 | -41.77 | -32.97 | -31.93 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 56.85 | 56.69 | 53.92 | 52.55 |
Diluted EPS Before Non-Recurring Items | NA | -0.68 | -0.74 | -0.61 | -0.61 |
Diluted Net EPS (GAAP) | NA | -0.68 | -0.74 | -0.61 | -0.61 |